Announcement • Jul 02
Eco Animal Health Group Plc Launches Ecovaxxin MS Poultry Vaccine In European Union Eco Animal Health Group plc announced the commercial launch of ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae (M. synoviae), across the European Union (EU) with its official launch event in Madrid, Spain. ECOVAXXIN® MS represents the first product from ECO's proprietary R&D pipeline to reach commercial market entry. The vaccine provides active immunisation of future layer and breeder chickens from four weeks of age, to reduce air-sac and foot-pad lesions and egg production losses caused by M. synoviae infections. The infection causes significant economic loss, particularly in laying hens, where egg production in affected layers can be reduced by 5-10%. ECO is leveraging its established commercial network, built for Aivlosin®, to deliver comprehensive market coverage with strategic distribution agreements in place across the major poultry markets in the EU, providing access to markets representing over 220 million layer-birds annually. The Company is also progressing registration in USA, Latin American and Asian markets. Announcement • Apr 14
Eco Animal Health Group plc Announces Appointment of Andrew Winder as Head of Business Development, Effective May 11, 2026 Eco Animal Health Group plc announced the appointment of Dr Andrew Winder as Head of Business Development, effective from May 11, 2026. Andrew brings extensive strategic business development expertise to ECO, with a proven track record of driving profitable growth across global animal health markets. Andrew most recently served as Strategic Business Development Lead at Norbrook Laboratories Ltd. (Norbrook), a global provider of veterinary pharmaceuticals. During his 14-year tenure at Norbrook, Andrew secured multiple co-development and distribution agreements, created a new global portfolio strategy that doubled the number of projects in Norbrook's pipeline, and negotiated distribution agreements with leading multi-national partners including Boehringer Ingelheim, Zoetis and Elanco. In his new role, Andrew will be responsible for identifying and securing strategic opportunities, including in-licensing partnerships to grow the Company's R&D pipeline. His appointment comes at a pivotal time as ECO progresses the EU commercial launch of its live vaccine for poultry, ECOVAXXIN MS, and continues to expand its position as a comprehensive solutions provider in animal health. Andrew holds a PhD in Pharmaceutical Sciences from the University of Ulster and a BSc (Hons) in Microbiology from Queens University Belfast. He has also served as a member of the Board of Directors for Animal Health Europe. Announcement • Apr 02
ECO Animal Health Group plc Announces Resignation of Frank Armstrong as Independent Non-Executive Director, Effective September 2026 ECO Animal Health Group plc announced that Frank Armstrong has informed the Board of his intention to step down from his role as Independent Non-Executive Director of the Company, effective following the conclusion of this year's Annual General Meeting (AGM), which is anticipated to be held in September 2026. Dr Armstrong, who also serves as Chair of the Remuneration Committee, was recently elected as the Senior Lay Member (Chair) of the Court (Board) of the University of Edinburgh, a role he will assume in August 2026. Given the duties associated with this role and the length of his tenure at ECO, Dr Armstrong has decided to retire from his position and will step down at the AGM. The Board has commenced a thorough search process to identify a suitable replacement. Price Target Changed • Mar 20
Price target increased by 14% to UK£1.79 Up from UK£1.57, the current price target is an average from 6 analysts. New target price is 77% above last closing price of UK£1.02. Stock is up 74% over the past year. The company is forecast to post earnings per share of UK£0.022 for next year compared to UK£0.025 last year. Announcement • Mar 20
Eco Animal Health Group plc Provides Earnings Guidance for the Year Ending 31 March 2026 ECO Animal Health Group plc provided earnings guidance for the year ending 31 March 2026. The consensus market expectations for revenue for the year is £83.5 million. Announcement • Mar 12
ECO Animal Health Group plc Announces United States Department of Agriculture Delivers Favourable Safety Assessment of ECOVAXXIN MG ECO Animal Health Group plc announced that the United States Department of Agriculture (USDA) has delivered a favourable safety assessment of ECOVAXXIN MG, the Company's live poultry vaccine targeting Mycoplasma gallisepticum. The USDA's review and acceptance of the Company's ECOVAXXIN MG safety data represents an important step towards securing marketing authorisation for the vaccine in the United States. The comprehensive risk assessment confirms that ECO meets the USDA's rigorous safety standards, with final regulatory submission for ECOVAXXIN MG currently anticipated in late 2027. As part of the US registration requirements, ECOVAXXIN MG was demonstrated to be safe not only for the target species (chickens) but also for non-target avian species including turkeys and quails. Importantly, the strain did not revert or increase in virulence after passage through chickens, confirming its stability. Price Target Changed • Mar 02
Price target decreased by 8.0% to UK£1.57 Down from UK£1.71, the current price target is an average from 5 analysts. New target price is 49% above last closing price of UK£1.06. Stock is up 76% over the past year. The company is forecast to post earnings per share of UK£0.024 for next year compared to UK£0.025 last year. Announcement • Feb 26
ECO Animal Health Group plc Announces EU Launch Plans for EcoVAXXIN® MS ECO Animal Health Group plc provided an update on its commercial launch strategy for ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae, across the European Union (EU). Following the European Commission granting marketing authorisation for ECOVAXXIN®® MS, announced in December 2025, ECO's management team are progressing a detailed commercialisation plan designed to deliver strategic market entry across key European territories throughout 2026 and 2027. ECOVAXXIN®MS clinical need: ECOVAXXIN® S provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synovia infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%. The launch positions ECO as a comprehensive Mycoplasma solutions provider, combining best-in-class prevention through ECOVAXXIN®® MS with market-leading treatment via its lead product Aivlosin®. Go-to-market strategy: ECO Animal Health will leverage its existing comprehensive commercial network, successfully built for Aivlosin®, for the commercialisation of ECOVAXXIN® MD, taking advantage of deep expertise and customer reach in established distribution channels, and supplementing where necessary with additional technical and geographical capabilities. The Company has secured agreements with key strategic distribution partners providing comprehensive coverage across the EU's major poultry markets. These partnerships provide access to markets representing over 220 million layer birds annually across the EU's top seven layer-producing countries. Phased launch strategy The ECOVAXXIN®™ MS pre-launch phase, currently underway, comprises distributor training programmes, technical assessment completion, establishment of distribution agreements, marketing, and customer segmentation activities across key markets. An official launch event will be held from 30 June to 1 July 2026 in Madrid, Spain, bringing together key opinion leaders, genetics companies, major layer producers and distribution partners from across Europe. This will be followed by several regional launch events between Third Quarter 2026 and First Quarter 2027 targeting key layer-producing countries. Financial impact The Company expects sales of ECOVAXXin® MS to be immediately margin accretive and anticipates a material contribution to EBITDA from the product's sales for the 2027/2028 financial year. Reported Earnings • Dec 03
First half 2026 earnings released: UK£0.005 loss per share (vs UK£0.025 loss in 1H 2025) First half 2026 results: UK£0.005 loss per share (improved from UK£0.025 loss in 1H 2025). Revenue: UK£39.4m (up 19% from 1H 2025). Net loss: UK£363.0k (loss narrowed 79% from 1H 2025). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Dec 01
Eco Animal Health Group plc Provides Group Revenue Guidance for the Second Half of Year Ending 31 March 2026 ECO Animal Health Group plc provided group revenue guidance for the year ended 31 March 2026. The Group expects that the historically observed increased demand for Aivlosin associated with the Northern Hemisphere winter will once again result in a stronger second half to year. 86% (H1 2024: 82%) of the market consensus revenue for the year ending 31 March 2026 is covered by year-to-date revenue, order books and run rate from the Group's stocking locations (excluding China). Announcement • Nov 20
ECO Animal Health Group plc to Report First Half, 2026 Results on Dec 01, 2025 ECO Animal Health Group plc announced that they will report first half, 2026 results on Dec 01, 2025 Announcement • Nov 10
ECO Animal Health Group plc Announces EMA Positive Opinion Received for EcoVAXXIN MS Poultry Vaccine ECO Animal Health Group plc announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion recommending the granting of EU marketing authorisation for ECOVAXXIN®? MS, a poultry vaccine against Mycoplasma synovia. Based on the CVMP's Positive Opinion, the EMA is expected to issue a marketing authorisation during the first quarter of 2026, and ECO Animal Health anticipates making ECOVAXXIN®?MS commercially available in the European Union in the second half of 2026. ECOVAXXIN®?®? MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions caused by Mycoplasma synoviae infections. Air-sac and foot- pad lesions cause economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%. ECO Animal Health expects to submit additional geographic marketing authorisation requests for ECOVAXXIN®®? MS, as well as submissions for further vaccine products in its R&D pipeline, during the next 12 months. New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (UK£61.7m market cap, or US$83.1m). Announcement • Sep 27
ECO Animal Health Group plc Provides Financial Guidance for the Six Months Ending 30 September 2025 ECO Animal Health Group plc provided financial guidance for the six months ending 30 September 2025. Trading in the first half of this financial year has been significantly stronger compared to the same period last year despite currency headwinds and tariff challenges, with an expected increase in revenue of over 15% (first half 2025: £33.2 million). The Company also expects to report improved gross margins for the period. Price Target Changed • Sep 26
Price target increased by 7.5% to UK£1.73 Up from UK£1.61, the current price target is an average from 5 analysts. New target price is 76% above last closing price of UK£0.98. Stock is up 0.5% over the past year. The company is forecast to post earnings per share of UK£0.025 for next year compared to UK£0.025 last year. Reported Earnings • Aug 29
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: UK£0.025 (up from UK£0.015 in FY 2024). Revenue: UK£79.6m (down 11% from FY 2024). Net income: UK£1.69m (up 61% from FY 2024). Profit margin: 2.1% (up from 1.2% in FY 2024). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Aug 28
ECO Animal Health Group plc, Annual General Meeting, Sep 25, 2025 ECO Animal Health Group plc, Annual General Meeting, Sep 25, 2025. Location: the grange, 100 high street, london n14 6bn United Kingdom New Risk • Jul 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (UK£51.8m market cap, or US$69.6m). Reported Earnings • Jul 14
Full year 2025 earnings released: EPS: UK£0.025 (vs UK£0.015 in FY 2024) Full year 2025 results: EPS: UK£0.025 (up from UK£0.015 in FY 2024). Revenue: UK£79.6m (down 11% from FY 2024). Net income: UK£1.69m (up 61% from FY 2024). Profit margin: 2.1% (up from 1.2% in FY 2024). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Jul 08
ECO Animal Health Group plc to Report Fiscal Year 2025 Results on Jul 14, 2025 ECO Animal Health Group plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Jul 14, 2025 Major Estimate Revision • Mar 25
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from UK£84.2m to UK£85.3m. EPS estimate increased from UK£0.022 to UK£0.024 per share. Net income forecast to grow 223% next year vs 32% growth forecast for Pharmaceuticals industry in the United Kingdom. Consensus price target down from UK£1.66 to UK£1.62. Share price was steady at UK£0.59 over the past week. Announcement • Mar 03
ECO Animal Health Group plc Announces Submission of Marketing Authorisation Application to EMA ECO Animal Health Group plc announced that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency ("EMA") for its ECOVAXXIN®? Mycoplasma synovia ("MS") vaccine. The submission marks an important milestone in the development of ECO's vaccines portfolio and its broader R&D pipeline. The submission is marginally ahead of plan with the formal approval process expected to take approximately 18 months, aligning with commercialisation strategy. Mycoplasma synoviae MS causes significant economic loss through joint and respiratory infections in poultry. Recent studies indicate that MS infection can reduce egg production by 5-10% in layers and breeders, decrease hatchability by 5-10%, and increase broiler mortality by 1-4%. Additionally, the disease negatively impacts feed conversion efficiency and performance, further reducing producer profitability. Maintenance of Mycoplasma synovIA free status on farms is generally difficult and infected birds may require antibiotic treatment. By the time clinical signs are visible, mycoplasma infection may have spread to in-contact birds, likely sub-clinical damage has already occurred and egg production impacted. Medication costs combine with reduced feed efficiency and performance losses to negatively impact producer profits. Announcement • Jan 31
ECO Animal Health Group plc Announces Board and Committee Changes ECO Animal Health Group plc announced that Dr Andrew Jones, who joined the Board as a Non-executive Director in 2017 and has served as Chairman of the Board since 2019, has stated his intention to retire on 31st March 2025. As part of a planned succession process, Dr Joachim Hasenmaier joined the Board as a Non-executive Director in February 2024 and will be appointed as Chairman of the Board of ECO on 31st March 2025. Dr Hasenmaier is a highly experienced commercial leader with more than two decades in the global animal health industry. From 2001 to 2019, he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as member of the Board of Managing Directors responsible for the entire animal health division. During this time, he led successful transformation initiatives including the integration of the former Sanofi animal health business Merial, spearheaded key product launches and supported rapid global growth and expansion. Dr Andrew Jones stepped down as Chairman of the Nomination Committee on 30 January 2025 and Dr Hasenmaier was appointed as Chairman of the Nomination Committee on the same day. On 31 March 2025, Dr Jones will also step down from the Audit and Remuneration Committees. There will be no further changes to the composition of these committees. Reported Earnings • Dec 01
First half 2025 earnings released: UK£0.025 loss per share (vs UK£0.019 loss in 1H 2024) First half 2025 results: UK£0.025 loss per share (further deteriorated from UK£0.019 loss in 1H 2024). Revenue: UK£33.2m (down 13% from 1H 2024). Net loss: UK£1.70m (loss widened 30% from 1H 2024). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. New Risk • Nov 29
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (UK£48.4m market cap, or US$61.5m). Price Target Changed • Nov 28
Price target decreased by 9.7% to UK£1.70 Down from UK£1.88, the current price target is an average from 4 analysts. New target price is 138% above last closing price of UK£0.71. Stock is down 31% over the past year. The company is forecast to post earnings per share of UK£0.024 for next year compared to UK£0.015 last year. Major Estimate Revision • Oct 02
Consensus EPS estimates fall by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from UK£92.6m to UK£87.3m. EPS estimate also fell from UK£0.029 per share to UK£0.024 per share. Net income forecast to grow 91% next year vs 46% growth forecast for Pharmaceuticals industry in the United Kingdom. Consensus price target down from UK£1.88 to UK£1.82. Share price fell 29% to UK£0.76 over the past week. New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£51.5m market cap, or US$68.4m). Major Estimate Revision • Aug 28
Consensus EPS estimates increase by 28% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from UK£0.022 to UK£0.029. Revenue forecast steady at UK£92.6m. Net income forecast to grow 153% next year vs 49% growth forecast for Pharmaceuticals industry in the United Kingdom. Consensus price target of UK£1.88 unchanged from last update. Share price was steady at UK£1.08 over the past week. Announcement • Aug 16
ECO Animal Health Group plc, Annual General Meeting, Sep 26, 2024 ECO Animal Health Group plc, Annual General Meeting, Sep 26, 2024. Location: the grange, 100 high street, n14 6bn, london United Kingdom New Risk • Jul 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£77.2m (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 16
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: UK£0.016 (up from UK£0.015 in FY 2023). Revenue: UK£89.4m (up 4.8% from FY 2023). Net income: UK£1.05m (up 4.0% from FY 2023). Profit margin: 1.2% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 34%. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Announcement • Jul 11
ECO Animal Health Group plc to Report Fiscal Year 2024 Results on Jul 15, 2024 ECO Animal Health Group plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Jul 15, 2024 Announcement • Apr 27
Eco Animal Health Group plc Provides Earnings Guidance for the Year 2024 ECO Animal Health Group plc provided earnings guidance for the year 2024. For the year, Board expected revenues to be in line with market expectations. Market expectations for FY24 Revenue as at the date of this announcement are £88.7 Million. With full visibility on trading for the year, the Company can report that final revenues were greater than market expectations and nearly £90 Million. Overperformance in revenue generation was achieved despite foreign exchange headwinds experienced in the early part of the financial year. When presented on a constant currency basis the Board expects to report revenue growth in excess of 10% over the year ended 31 March 2023. Announcement • Mar 23
ECO Animal Health Group plc Provides Revenue Guidance for the Full Year Ending 31 March 2024 ECO Animal Health Group plc provided revenue guidance for the full year ending 31 March 2024. For the period, the company expects that revenue for the full year ending 31 March 2024, will be in-line with market expectations which is £88.7 million. Announcement • Feb 12
ECO Animal Health Group plc Appoints Joachim Hasenmaier as Non-Executive Director ECO Animal Health Group plc announced the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director, with immediate effect. Dr. Hasenmaier is a highly experienced commercial leader with more than two decades in the international animal health industry. From 2001 to 2019 he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as member of the Board of Managing Directors responsible for the entire animal health division. During this time he led successful transformation initiatives including the integration of the former Sanofi animal health business Merial, spearheaded key product launches and supported rapid global growth and expansion. Dr. Hasenmaier has also served as Chairman of the Board at IMV Technologies since 2022 and as a Member of the Supervisory Boards of Invetx. He served on the Board of NASDAQ-listed Heska prior to its acquisition by Mars Petcare. He also held senior positions at Hoechst Roussel Vet and McKinsey & Company. Dr. Hasenmaier is a Doctor of Veterinary Medicine and holds a PhD in Immunology from Ludwig-Maximillians University in Munich. has an MBA from Northwestern University, USA. Announcement • Feb 06
ECO Animal Health Group plc Announces the ECOVAXXIN Family in the EU ECO Animal Health Group plc announced that the ECOVAXXIN®? trademark has been approved by the European Union ("EU"). In addition to this EU trademark ECOVAXXIN®? has also been registered in the USA and in the UK, giving extensive protection in key markets for animal health products. The registration for ECOVAXXIN®? provides trademark branding for a family of vaccine products. ECOVAXXIN®? is a master trademark and will protect all ECO's forthcoming vaccine products. Starting in 2025, the Company plans to market its vaccine products in multiple jurisdictions, with multiple planned launches over the next ten year period. The first two planned products to carry the trademark will be the Company's poultry mycoplasma vaccines, specifically ECOVAXXIN®? MS, a vaccine against Mycoplasma Synoviae, and ECOVAXXIN®? MG, a vaccine against Mycplasma Gallisepticum. The trademark approval supports ECO's strategy of accelerating growth through the Company's research and development pipeline. The addition of new vaccines is expected to significantly support sales and profit growth over the next ten years. Reported Earnings • Nov 29
First half 2024 earnings released: UK£0.019 loss per share (vs UK£0.02 profit in 1H 2023) First half 2024 results: UK£0.019 loss per share (down from UK£0.02 profit in 1H 2023). Revenue: UK£38.0m (up 9.0% from 1H 2023). Net loss: UK£1.31m (down 199% from profit in 1H 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Price Target Changed • Nov 20
Price target increased by 18% to UK£1.86 Up from UK£1.58, the current price target is an average from 4 analysts. New target price is 65% above last closing price of UK£1.13. Stock is up 26% over the past year. The company is forecast to post earnings per share of UK£0.025 for next year compared to UK£0.015 last year. Announcement • Oct 25
ECO Animal Health Group plc Announces New USA and Canada Label Claim for Aivlosin® ECO Animal Health Group plc to announce that it has received a new US and Canadian label claim indication for Aivlosin® Water Soluble Granules ("WSG") in pigs. Following years of research into the sow reproductive safety of Aivlosin® WSG, a new 'sow safety' indication has been approved by the US Food & Drug Administration (FDA). Prior to this approval, the label indication restricted WSG to be used only in the drinking water of swine intended for slaughter and not for use in lactating or pregnant females, or males and females intended for breeding. The new label indication will be 'For use only in the drinking water of swine intended for slaughter and female swine intended for breeding. Not for use in male swine intended for breeding'. Meanwhile, the Veterinary Drugs Directorate in Canada has also approved the removal of label statements regarding 'not for use in lactating or pregnant females and females intended for breeding'. Announcement • Jul 24
ECO Animal Health Group plc, Annual General Meeting, Sep 07, 2023 ECO Animal Health Group plc, Annual General Meeting, Sep 07, 2023, at 13:30 Coordinated Universal Time. Location: Grange, 100 High Street London United Kingdom Major Estimate Revision • Jul 17
Consensus EPS estimates fall by 37% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£90.0m to UK£88.2m. EPS estimate also fell from UK£0.038 per share to UK£0.024 per share. Net income forecast to grow 64% next year vs 69% growth forecast for Pharmaceuticals industry in the United Kingdom. Consensus price target down from UK£1.58 to UK£1.50. Share price rose 3.9% to UK£1.08 over the past week. Reported Earnings • Jul 10
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: UK£0.015 (up from UK£0.01 loss in FY 2022). Revenue: UK£85.3m (up 3.8% from FY 2022). Net income: UK£1.01m (up UK£1.69m from FY 2022). Profit margin: 1.2% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Announcement • Jul 06
ECO Animal Health Group plc to Report Fiscal Year 2023 Results on Jul 10, 2023 ECO Animal Health Group plc announced that they will report fiscal year 2023 results on Jul 10, 2023 Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to UK£1.14, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£1.83 per share. Major Estimate Revision • Mar 24
Consensus EPS estimates increase by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from UK£83.0m to UK£83.9m. EPS estimate increased from UK£0.024 to UK£0.03 per share. Net income forecast to grow 71% next year vs 80% growth forecast for Pharmaceuticals industry in the United Kingdom. Consensus price target broadly unchanged at UK£2.06. Share price rose 2.4% to UK£1.07 over the past week. Buying Opportunity • Mar 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.2%. The fair value is estimated to be UK£1.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 39%. Revenue is forecast to grow by 15% in 2 years. Earnings is forecast to grow by 134% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to UK£1.03, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 19x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£1.41 per share. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improved over the past week After last week's 20% share price gain to UK£1.05, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£1.71 per share. Reported Earnings • Nov 24
First half 2023 earnings released: EPS: UK£0.02 (vs UK£0.009 loss in 1H 2022) First half 2023 results: EPS: UK£0.02 (up from UK£0.009 loss in 1H 2022). Revenue: UK£34.9m (down 9.4% from 1H 2022). Net income: UK£1.33m (up UK£1.95m from 1H 2022). Profit margin: 3.8% (up from net loss in 1H 2022). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Frank Armstrong was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: UK£0.01 loss per share (down from UK£0.12 profit in FY 2021). Revenue: UK£82.2m (down 22% from FY 2021). Net loss: UK£686.0k (down 108% from profit in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to stay flat compared to a 2.1% decline forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Board Change • Aug 10
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Chairman Andy Jones is the most experienced director on the board, commencing their role in 2017. Independent Non-Executive Director Frank Armstrong was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Major Estimate Revision • Aug 09
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from UK£0.02 to UK£0.02. Revenue forecast steady at UK£81.4m. Net income forecast to shrink 65% next year vs 11% growth forecast for Pharmaceuticals industry in the United Kingdom . Consensus price target down from UK£2.92 to UK£2.71. Share price fell 18% to UK£1.00 over the past week. Buying Opportunity • Aug 08
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be UK£1.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has declined by 9.7%. Revenue is forecast to decline by 10% in 2 years. Earnings is forecast to decline by 27% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 19% share price gain to UK£1.26, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£1.40 per share. Buying Opportunity • Jun 29
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be UK£1.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has declined by 9.7%. Revenue is forecast to decline by 10% in 2 years. Earnings is forecast to decline by 27% in the next 2 years. Recent Insider Transactions • Apr 02
CFO, Finance Director recently bought UK£56k worth of stock On the 29th of March, Christopher Wilks bought around 35k shares on-market at roughly UK£1.60 per share. In the last 3 months, they made an even bigger purchase worth UK£70k. Christopher has been a buyer over the last 12 months, purchasing a net total of UK£216k worth in shares. Board Change • Apr 02
Less than half of directors are independent Following CEO & Director David Hallas' arrival on 01 April 2022, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Frank Armstrong was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 24
CFO, Finance Director recently bought UK£70k worth of stock On the 18th of March, Christopher Wilks bought around 50k shares on-market at roughly UK£1.40 per share. This was the largest purchase by an insider in the last 3 months. Christopher has been a buyer over the last 12 months, purchasing a net total of UK£120k worth in shares. Major Estimate Revision • Mar 16
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 consensus EPS estimate fell from UK£0.03 to UK£0.02. Revenue forecast reaffirmed at UK£81.3m. Net income forecast to shrink 58% next year vs 20% growth forecast for Pharmaceuticals industry in the United Kingdom . Consensus price target down from UK£3.01 to UK£2.92. Share price fell 19% to UK£1.30 over the past week. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorated over the past week After last week's 21% share price decline to UK£1.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorated over the past week After last week's 20% share price decline to UK£1.73, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 23x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 61% over the past three years. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improved over the past week After last week's 19% share price gain to UK£2.20, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 20x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 30% share price gain to UK£1.98, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 23x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 55% over the past three years. Reported Earnings • Nov 27
First half 2022 earnings: EPS and revenues exceed analyst expectations First half 2022 results: UK£0.002 loss per share (down from UK£0.036 profit in 1H 2021). Revenue: UK£38.5m (down 9.5% from 1H 2021). Net loss: UK£140.0k (down 106% from profit in 1H 2021). Revenue exceeded analyst estimates by 4.7%. Earnings per share (EPS) missed analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 9.8% compared to a 18% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment deteriorated over the past week After last week's 28% share price decline to UK£1.60, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 21x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 63% over the past three years. Price Target Changed • Nov 25
Price target decreased to UK£3.50 Down from UK£4.53, the current price target is an average from 3 analysts. New target price is 119% above last closing price of UK£1.60. Stock is down 33% over the past year. The company is forecast to post earnings per share of UK£0.095 for next year compared to UK£0.12 last year. Upcoming Dividend • Sep 16
Upcoming dividend of UK£0.01 per share Eligible shareholders must have bought the stock before 23 September 2021. Payment date: 22 October 2021. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (3.9%). Lower than average of industry peers (3.5%). Reported Earnings • Jul 27
Full year 2021 earnings released: EPS UK£0.12 (vs UK£0.038 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£105.6m (up 47% from FY 2020). Net income: UK£8.16m (up 216% from FY 2020). Profit margin: 7.7% (up from 3.6% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Mar 08
New 90-day high: UK£3.68 The company is up 48% from its price of UK£2.48 on 08 December 2020. The British market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£1.72 per share. Reported Earnings • Feb 06
Full year 2020 earnings released: EPS UK£0.038 (vs UK£0.18 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£72.1m (down 3.3% from FY 2019). Net income: UK£2.58m (down 78% from FY 2019). Profit margin: 3.6% (down from 16% in FY 2019). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Feb 06
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 27%. Over the next year, revenue is forecast to grow 26%, compared to a 11% growth forecast for the Pharmaceuticals industry in the United Kingdom. Announcement • Feb 05
ECO Animal Health Group plc, Annual General Meeting, Mar 04, 2021 ECO Animal Health Group plc, Annual General Meeting, Mar 04, 2021, at 13:30 Coordinated Universal Time. Is New 90 Day High Low • Feb 05
New 90-day high: UK£3.25 The company is up 40% from its price of UK£2.33 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£2.82 per share. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improved over the past week After last week's 31% share price gain to UK£3.25, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 18x in the Pharmaceuticals industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 35%. Announcement • Jan 13
ECO Animal Health Group plc Receives Marketing Authorisations from the United States Center for Veterinary Medicine of the Food and Drug Administration and from the Veterinary Drugs Directorate of Health Canada for Aivlosin ECO Animal Health Group plc announced that it has received marketing authorisations from the United States Center for Veterinary Medicine of the Food and Drug Administration and from the Veterinary Drugs Directorate of Health Canada for Aivlosin. These approvals of Aivlosin Water Soluble Granules add Mycoplasma hyopneumoniae to the list of pathogens indicated for the control of swine respiratory disease ("SRD"). M. hyopneumoniae is a primary pathogen in swine respiratory disease complexes playing an important role in facilitating the entry of bacterial and viral pathogens. SRD occurs worldwide and causes major economic losses to the pig industry. Aivlosin Water Soluble Granules is under the control of North American veterinarians and is available under prescription only. It has a low, highly effective dose rate, short treatment duration and a zero day drug withholding period. The product will be marketed through Pharmgate Animal Health, the Group's well-established sales and marketing joint operation with Pharmgate Corp. (the majority-owned US subsidiary of Jinhe Biotechnology Co. Ltd., P. R. China). Is New 90 Day High Low • Dec 12
New 90-day high: UK£2.58 The company is up 7.0% from its price of UK£2.40 on 11 September 2020. The British market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£5.44 per share. 